Regression of left ventricular hypertrophy in hemodialysis patients is possible;Eine regression der linksventrikulären hypertrophie bei hämodialysepatienten ist möglich

Nieren- und Hochdruckkrankheiten

Volumn 31, Issue SUPPL. 1, 2002, Pages

  Hampl, Hannelore ^a   Sternberg, C ^a   Berweck, S ^a   Lange, D ^a   Lorenz, F ^a   Pohle, C ^a   Riedel, E ^a   Gogoll, L ^a   Hennig, L ^a  

^a KfH Kuratorium Für Dialyse and Nierentransplantation E v Dialysezentrum   (Germany)

Author keywords

ACE inhibitors; Angiotensin II receptor blockers, antihypertensives, combination therapies; Cardio renal syndrome of anemia; Left ventricular hypertrophy regression; Renal anemia total correction

Indexed keywords

AMLODIPINE BESYLATE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN HEXETIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN; METOPROLOL TARTRATE; RAMIPRIL; SPIRONOLACTONE;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTIHYPERTENSIVE THERAPY; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DIALYSIS; DISEASE COURSE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0037184346     PISSN: 03005224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (105)

1. Schäfer G.E. et al.: Hemodynamic response to chronic anemia in renal failure. Contrib. Nephrol. 41, 428-432 (1984).
2. Schäfer G.E. et al.: Veränderungen der herz-kreislauf-funktion bei chronischer niereninsuffizienz. Nieren- Hochdruckkrkh. 13, 167-174 (1984).
3. Hampl H. et al.: Hemodynamic state in severe chronic renal failure. Nephron 39, 102-111 (1985).
4. Schäfer G.E. et al: Störungen der herz- und kreislauffunktionen bei präterminaler niereninsuffizienz und ihre veränderungen unter chronischer hämodialyse. In: Dittrich P. von et al. (Hrsg): Aktuelle Probleme der Dialyseverfahren und der Niereninsuffizienz. Bindernagel, Friedberg 1981.
5. Hampl H. et al.: Advantages of bicarbonate hemodialysis. Artif. Organs 6, 410-416 (1982).
6. Foley R.N. et al.: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 47, 186-192 (1995).
7. Parfrey P.S. et al.: The clinical epidemiology of cardiac disease in chronic renal failure. J. Am. Soc. Nephrol. 10, 1606-1615 (1999).
8. London G. et al.: Cardiac disease in chronic uremia. Pathogenesis. Adv. Renal. Replace Ther. 4, 194-211 (1997).
9. Ritz E. et al.: Optimal hemoglobin during treatment with recombinant human erythropoietin. Nephrol. Dial. Transplant. 13 (Suppl. 2), 16-22 (1998).
10. Foley R.N. et al.: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J. Am. Soc. Nephrol 5, 2024-2031 (1995).
11. Gauer O.H. et al.: Physiologie des Menschen. Band 3: Herz und Kreislauf. Urban u. Schwarzenberg, München 1972, 148-160.
12. Bretschneider H.J.: Aktuelle probleme der koronardurchblutung und des myokardstoffwechsels. Regensb. Jb. Ärztl. Fortb. XVII, 1-5 (1967).
13. Mall G. et al.: Diffuse intercardiomyocytic fibrosis in uremic patients Nephrol. Dial. Transplant. 5, 39-44 (1990).
14. Amann K. et al.: Reduced capillary density in the myocardium of uremic rats- A stereological study. Kidney Int. 42, 1097-1085 (1987).
15. Verdecchia P. et al.: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97, 48-54 (1998).
16. Koren M.J. et al.: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. 114, 345-352 (1991).
17. London G.M. et al.: Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. Kidney Int. 31, 973-980 (1987).
18. Macdougall L.C. et al.: Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet 335, 489-493 (1990).
19. Goldberg N. et al.: Changes in left ventricular size, wall thickness and function in anemic patients treated with recombinant human erythropoietin. Am. Heart J. 124, 424-427 (1992).
20. Silberberg J. et al.: Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant erythropoietin. Can. J. Cardiol. 6, 1-4 (1990).
21. Pascual J. et al.: Hemodynamic and cardiac effects of erythropoietin in patients on regular dialysis. Int. J. Artif. Organs. 15, 349-353 (1992).
22. Sikole A. et al.: Analysis of heart morphology and functions following erythropoietin treatment of anemic dialysis patients. Artif. Organs 17, 977-984 (1993).
23. Wizemann V. et al.: Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left ventricular hypertrophy. Nephron 64, 202-206 (1993).
24. Hampl H. et al.: Recurrent hyperparathyroidism after total parathyreoidectomy and autotransplantation in patients with long-term hemodialysis. Mineral. Electrolyte Metab. 17, 256-260 (1991).
25. Hampl H. et al.: An argument for total parathyreoidectomy. Tenth Workshop on Vitamin D Strasbourg/France, May 24 - 29. Abstracts, page 162 (1997).
26. Hampl H. et al.: Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure: An argument for total parathyroidectomy alone. Mineral Electrolyte Metab. 25, 161-170 (1999).
27. Hampl H.: Was spricht für eine vollständige korrektur der renalen anämie? Nieren- Hochdruckkrkh. 28 (Suppl. 1), 1-81 (1999).
28. Hampl H. et al.: What speaks in favor of a complete correction of renal anemia? Clin. Nephrol. 53 (Suppl. 1), 1-89 (2000).
29. Devereux R.B. et al.: Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 55, 613-618 (1977).
30. US Renal Data Service: Annual Data Report 1999.
31. Hampl H. et al.: Prävention der kardialen morbidität und mortalität bei urämikern. Therapeutische strategien mit besonderer beachtung der rcnalen anämie. Nieren- Hochdruckkrkh. 29, 566-572 (2000).
32. Sommerburg O. et al.: Does long-term treatment of renal anemia with rhEPO influence oxidative stress in hemodialysis patients? Nephrol. Dial. Transplant 13, 2583-2587 (1998).
33. Siems W. et al.: Erythrocyte free radical and energy metabolism Clin. Nephrol. 53 (Suppl. 1), 9-17 (2000).
34. Grune T. et al.: Oxidative stress in anemia. Clin. Nephrol. 53 (Suppl. 1), 18-22 (2000).
35. McMahon L.P. et al.: Physical performance and associated electrolyte change after hemoglobin normalization: A comparative study in hemodialysis patients. Nephrol. Dial. Transplant. 14, 1182-1187 (1999).
36. Eschbach J. W. et al.: Normalizing the hematocrit in hemodialysis patients with EPO improves quality of life and is safe. J. Am. Soc. Nephrol. 4, 425 (1993).
37. McMahon L.P. et al.: Effects of hemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol. Dial. Transplant. 15, 1425-1430 (2000).
38. Macdougall L.C. et al.: Should the hematocrit be normalized in dialysis and in pre-ESRD patients? Blood Purif. 19, 157-167 (2001).
39. Beserab A. et al.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoitin. J. Am. Soc. Nephrol. 9, 337A (1998).
40. Furnland H. et al.: Cardiac function in patients with end-stage renal disease after normalization of hemoglobin with erythropoietin. J. Am. Soc. Nephrol. 9, 337A (1998).
41. Furnland H. et al.: Physical exercise capacity in patients with end-stage renal disease after normalization of hemoglobin with erythropoietin. J. Am. Soc. Nephrol. 9, 337A (1998).
42. Foley R.N. et al. and the Canadian normalization of hemoglobin study group: A randomized controlled trial of complete vs partial correction of anemia in hemodialysis patients with asymptomatic concentric LV-hypertrophy or LV-dilatation. J. Am. Soc. Nephrol. 9, 208A (1998).
43. NKF-DOQI Work Group: NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am. J. Kidney Dis. 30 (Suppl. 3), 192-240 (1997).
44. European best practice guidelines for the management of anemia in patients with chronic renal, failure. Nephrol. Dial. Transplant. 14 (Suppl. 5), 1-50 (1999).
45. Duchesne-Guegnen M. et al.: Study of hemorheological parameters in patients with chronic renal failure and evolution of those parameters in course of dialysis treatment. Clin. Hemorheol. 8, 407-414 (1988).
46. Lerche D. et al.: Flow properties of blood and hemorheological methods of quantification. In: Schütt W. et al.: Physical Characterization of Biological Cells. Gesundheit, Berlin 1991, 189-214.
47. Lerche D. et al.: Rheology in whole blood and in red blood cells under rhEPO therapy. In: Baldamus G.A. et al.: Erythropoietin: From molecular structure to clinical application. Contrib. Nephrol. 76, Karger, Basel 299-305 (1989).
48. Meyer W. et al.: Action of rhEPO on mechanical membrane properties of red blood cells of children with end-stage renal disease. Nephrol. Dial. Transplant. 7, 1199-1206 (1991).
49. Meyer W. et al.: Microrheological properties of uremic RBC. Alterations due to rhEPO therapy Studia Biophysica 134, 161-166 (1989).
50. Schmidt R. et al.: Changes in rheology and red blood cell function under rhEPO therapy. Pol. Arch. Med. Wewnet. 85, 384-390 (1991).
51. Siems W. et al.: Changed purine nucleotide concentrations and enzyme activities in erythrocytes of hemodialysis patients undergoing rhEPO therapy. Eur. J. Clin. Chem. Clin. Biochem. 30, 455-460 (1992).
52. Hampl H. et al.: Erythropoiesis and erythrocyte age distribution in hemodialysis patients undergoing rhEPO therapy. Blood Purif. 8, 117-125 (1990).
53. Paulitschke M. et al.: Long-term effects of rhEPO therapy on erythrocyte rheology in dialysis patients with different target hematocrits. Clin. Nephrol. 53 (Suppl. 1), 36-41 (2000).
54. Ludat K. et al.: Complete correction of renal anemia by rhEPO: Hemodialysis - ultrafiltration - blood rheology - whole blood viscosity - RBC aggregation - RBC deformability. Clin. Nephrol. 53 (Suppl. 1), 42-49 (2000).
55. Ludat K. et al.: Oxidation parameters in complete correction of renal anemia. Clin. Nephrol. 53 (Suppl. 1), 30-35 (2000).
56. Polaschegg H.D.: Pressure and flow in the extracorporeal circuit. Clin. Nephrol. 53 (Suppl. 1), 50-55 (2000).
57. Moreno F. et al.: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish cooperative renal patients quality of life study group of the Spanish Society of Nephrology. J. Am. Soc. Nephrol. 11, 335-342 (2000).
58. Siems W. et al.: Elevated serum concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to the degree of renal anemia. Clin. Nephrol. (s. Beitrag in diesem Heft) (2002).
59. Parfrey S.P. et al.: Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 49, 1428-1434 (1996).
60. Hampl H. et al.: How can hemodialysis-associated hypotension and dialysis-induced symptoms be explained and controlled - Particularly in diabetic and arteriosclerotic patients. Clin. Nephrol. 53 (Suppl. 1), 69-79 (2000).
61. Canella G. et al.: Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients. Kidney Int. 58, 260-268 (2000).
62. Siems W. et al.: Oxidative stress in chronic renal failure as cardiovascular risk factor. Clin. Nephrol. (s. Beitrag in diesem Heft) (2002).
63. Levy D. et al.: Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors: The Framingham Heart Study. Ann. Intern. Med. 108, 7-13 (1988).
64. Levy D. et al.: Left ventricular mass and incidence of coronary heart disease in an elderly cohort: The Framingham Heart Study. Ann. Int. Med. 110, 101-107 (1989).
65. Alderman M.H.: Blood pressure management: Individualized treatment based on absolute risk and the potential for benefit. Ann. Intern. Med. 119, 329-335 (1993).
66. Devereux R.B. et al.: What is normal blood pressure? Comparison of ambulatory pressure level and variability in patients with normal or abnormal left ventricular geometry. Am. J. Hypertens. 6, 211-215 (1993).
67. Conlon P.J. et al.: Prädialytic systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J. Am. Soc. Nephrol. 7, 2658-2663 (1996).
68. Foturk S. et al.: Relationship of ambulatory blood pressure monitoring data to echocardiographic findings in hemodialysis patients. Nephrol. Dial. Transplant. 11, 2050-2054 (1996).
69. Kirchner K.A. et al.: Hypertension in hemodialysis patients: More questions than answers. Am. J. Kidney Dis. 30, 577-578 (1997).
70. Cheigh J.S. et al.: Hypertension is not adequately controlled in hemodialysis patients. Am. J. Kidney Dis. 19, 453-459 (1992).
71. The sixth report 1997 of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of high blood pressure. Arch. Int. Med. 157, 2413-2447 (1997).
72. Luik A. et al.: Abstract. J. Am. Soc. Nephrol. 5, 521 (1996).
73. Mailux L. et al.: Hypertension in the hemodialysis population. Am. J. Kidney Dis. 29, 811-814 (1997).
74. Brown J.J. et al.: Plasma renin concentration and the control of blood pressure in patients on maintenance hemodialysis. Nephron 6, 329-349 (1969).
75. Vertis V. et al.: Hypertension in end-stage renal disease. N. Engl. J. Med. 280, 978-981 (1969).
76. Wilkinson R. et al.: Plasma renin and exchangeable sodium in the hypertension of chronic renal failure. Am. J. Med. 39, 377-394 (1970).
77. Salem M.M. et al.: Hypertension in the dialysis population. A survey of 649 patients. Am. J. Kidney Dis. 26, 461-468 (1995).
78. Luik A. et al.: Hypertension in the dialysis patients: Is it only hypervolemia? Nephrol. Dial. Transplant. 12, 1557-1560 (1997).
79. Grekas D. et al.: Hypertension in chronic hemodialysis patients: Current view on pathophysiology and treatment. Clin. Nephrol. 53, 164-168 (2000).
80. Zuccala A. et al.: Pathogenesis of hypertension in hemodialysis patients: A pharmacological study. Kidney Int. 34 (Suppl. 24), 190-191 (1988).
81. Yamamoto T. et al.: Role of angiotensin II in the pathogenesis of hyperdypsia in chronic renal failure. JAMA 256, 604-608 (1986).
82. Acchiardo S.R. et al.: Automated ambulatory blood pressure monitoring of hemodialysis patients. J. Am. Soc. Nephrol. 5, 555 (1994).
83. Bastani B. et al.: Lack of efficacy of ACE inhibitors in reducing interdialytic weight gain. Am. J. Kidney Dis. 24, 907-911 (1994).
84. Charra B. et al.: Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. Am. J. Nephrol. 16, 35-44 (1996).
85. Krautzig S. et al.: Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance hemodialysis patients. Nephrol. Dial. Transplant. 13, 522-553 (1998).
86. Converse R.L. et al.: Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 327, 1912-1918 (1992).
87. Ritz E. et al.: The effect of malnutrition on cardiovascular mortality in dialysis patients: Is L-arginine the answer? Nephrol. Dial. Transplant. 9, 129-130 (1994).
88. Bergström J. et al.: Dialysis ultrafiltration and blood pressure. Proc. Eur. Dial. Transplant. Assoc. 13, 293 (1976).
89. Hampl H. et al.: Advantages of bicarbonate dialysis. Artif. Organs 6, 410-416 (1982).
90. Morimoto A. et al.: Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 350, 1734-1737 (1997).
91. Kaplan N.M. et al.: Primary hypertension: Pathogenesis. In: Kaplan N.M. (ed.): Clinical Hypertension. 7th Edition. Williams and Wilkins, Baltimore 1998, 41-100.
92. Julius S. et al.: The changing face of sympathetic overactivity in hypertension. Ann. Med. 32, 356-370 (2000).
93. Weber M.A. et al.: Differing roles of body mass and the renin-angiotensin system in mediating the hypertens. Syndrome. Am. J. Nephrol. 20, 69-174 (2000).
94. The heart outcomes prevention evaluation study investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
95. Kaplan N.M.: Primary hypertension: Pathogenesis. In: Kaplan N.M. (ed.): Clinical Hypertension. 6th Edition. Williams and Wilkins, Baltimore, 1994, 133-139.
96. Unger T. et al.: Angiotensin receptor. J. Hypertension 14 (Suppl. 5), 95-103 (2000).
97. Cohn J.N. et al.: Base line demographies of the valsartan heart failure trial. Val-Heft investigators. Eur. J. Heart Fail. 2, 439-446 (2000).
98. McKelvie R.S. et al.: RESOLVD-Pilot Study. Circulation 100, 1056-1064 (1999).
99. Roig E. et al.: Clinicl implications of increased plasma angiotensin-11 despite ACE-inhibitor therapy. Eur. Heart J. 21, 53-57 (2000).
100. London G.M. et al.: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J. Am. Soc. Nephrol. 12, 2759-2767 (2001).
101. Silverberg D.S. et al.: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemie of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. (JACC) 35, 1737-1744 (2000).
102. Silverberg D.S. et al.: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J. Am. Coll. Cardiol. (JACC) 37, 1775-1780 (2001).
103. Goodnough L. et al.: Anemia, transfusion and mortality. N. Engl. J. Med. 345, 1272-1274(2001).
104. Al-Ahmad A. et al.: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. (JACC) 38, 955-962 (2001).
105. Wen-Chih Wu et al.: Blood transfusion in elderly patients with acute myocardial infarction. N. Engl. J. Med. 345, 1230-1236 (2001).